NCT07487571Not yet recruiting
MPV as a Predictor for ACS in Patients With MASLD
Mean Platelet Volume as a Predictor for Acute Coronary Syndrome in Patients With Metabolic Dysfunction-associated Steatotic Liver Disease
Source: ClinicalTrials.gov · Last updated 6 May 2026
Brief summary (registry, in English)
The aim of this study is to evaluate mean platelet volume (MPV) as a predictor of acute coronary syndrome (ACS) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD to evaluate mean platelet volume (MPV) as a predictor of acute coronary syndrome (ACS) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) in Sohag University Hospital.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 60 (estimated)
- First submitted
- 17 Mar 2026
- Start date
- 5 May 2026
- Primary completion date
- 1 Nov 2026
- Lead sponsor
- Sohag University
- NCT number
- NCT07487571
What you commit to
- Study type: Observational
- Planned participants: 60
- From 5 May 2026 to the primary completion date, 1 Nov 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients receiving antiplatelet or anticoagulant therapy prior to blood sampling.
Other illness
- Patients with chronic liver diseases other than MASLD (e.g., viral hepatitis, autoimmune hepatitis, alcoholic liver disease).
- Patients with active infection, inflammatory diseases, or malignancy.
- Patients with chronic kidney disease or end-stage renal failure.
Lab values
- Patients with known hematological disorders affecting platelet count or function.
Other
- Pregnant or lactating females.
Who the study is looking for
- Adult patients aged ≥18 years.
- Confirmed diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD) based on clinical, laboratory, and imaging criteria).
- Patients diagnosed with acute coronary syndrome (unstable angina, NSTEMI, or STEMI) for Group I.
- MASLD patients without clinical or electrocardiographic evidence of acute coronary syndrome for Group II.
- Patients who provide informed consent to participate in the study.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Sohag University Hospital Coordinator of this site? Confirm its status | Sohag | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.